An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects

Daprodustat increased hemoglobin concentrations within the target range in 29% of chronic rhEPO-hyporesponsive subjects. No new safety concerns were identified in this short exploratory study.